New discovery sheds light on how bacteria use plasmids to build resistance

An international collaboration has achieved an important breakthrough in understanding the genetic mechanisms that allow bacteria to build resistance to drugs.

Actimed plans trials to treat muscle wasting syndrome in cancer patients

Actimed plans to start two Phase IIb/III trials of its lead candidate in H1 2024. Credit: Shutterstock / Casa nayafana. UK-based Actimed Therapeutics is planning

July 13, 2023

Senate confirms Monica Bertagnolli as NIH director

Longtime cancer doctor Monica Bertagnolli is finally heading to the National Institutes of Health director’s office after a nearly two-year effort to install a permanent

November 7, 2023

Merck CEO indicates interest in GLP-1 combination therapies, may pursue deals

Not wanting to be left out in the cold, Merck now plans to pursue GLP-1 combination therapies amid growing excitement about the lucrative potential of a drug class that

January 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.